Botanical Therapeutics for Parkinson's Disease

被引:2
作者
Li, Wen-wei [1 ,2 ,3 ]
机构
[1] Fudan Univ, Dept Neurol, Shanghai Publ Hlth Clin Ctr, Shanghai 201500, Peoples R China
[2] Fudan Univ, Zhongshan Hosp South Branch, Dept Neurol, Shanghai 201500, Peoples R China
[3] Fudan Univ, Inst Integrat Med, Inst Neurol, Shanghai 201500, Peoples R China
基金
中国国家自然科学基金;
关键词
Parkinson's disease; botanical therapeutics; Chinese medicine; neurotrophic activity; protein aggregation; neuroinflammation; TRADITIONAL CHINESE MEDICINE; CLINICAL DIAGNOSTIC-CRITERIA; ALPHA-SYNUCLEIN; WITHANIA-SOMNIFERA; MUCUNA-PRURIENS; DOUBLE-BLIND; AUTOPHAGY; DOPAMINE; CLEARANCE; MICROGLIA;
D O I
10.1007/s11655-020-3096-5
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Parkinson's disease (PD) was first formally described by James Parkinson in 1817, but the shaking of limbs was described in the literature of several ancient civilizations, such as ancient Chinese civilization and ancient Indian civilization. Historically, botanical drugs were used as the main source for the treatment of such kind of disorders. In Western countries, plant extracts also occupied an important place in the earlier medications of PD. With the adventure of synthetic drugs, the role of plant-derived drugs in management of PD has been diminished. Nowadays, there is still no cure for PD, dopaminergic (DA) medication is the treatment of choice, which is just designed to ameliorate symptoms of PD, and long-term use of DA medication will result in reduced efficacy and severe adverse reactions. It is necessary to explore new methods for the treatment of PD. Chinese medicine (CM) developed a holistic and unique theoretical system, and botanical drugs are widely used in practice for more than two millennia. Modern pharmacological studies have proved that Chinese herbs have potential therapeutic effects on PD, such as enhancing neurotrophic activity, clearing protein aggregates, regulating neuroinflammation, etc. All the advances provide us with hope for developing CM as a mainstream medication for treating PD.
引用
收藏
页码:405 / 411
页数:7
相关论文
共 81 条
[1]  
Ahmad M, 2005, HUM EXP TOXICOL, V24, P137, DOI [10.1191/0960327105ht509oa, 10.1191/0906327105ht209oa]
[2]  
[Anonymous], 1817, An Essay on the Shaking Palsy
[3]   Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease [J].
Antonini, Angelo ;
Poewe, Werner .
LANCET NEUROLOGY, 2007, 6 (09) :826-829
[4]   Preliminary optimization of a Chinese herbal medicine formula based on the neuroprotective effects in a rat model of rotenone-induced Parkinson's disease [J].
Bao, Xu-xia ;
Ma, Hui-han ;
Ding, Hao ;
Li, Wen-wei ;
Zhu, Min .
JOURNAL OF INTEGRATIVE MEDICINE-JIM, 2018, 16 (04) :290-296
[5]   Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations [J].
Carbone, Federico ;
Djamshidian, Atbin ;
Seppi, Klaus ;
Poewe, Werner .
CNS DRUGS, 2019, 33 (09) :905-918
[6]  
Chen HZ, 2017, J TRADIT CHIN MED, V37, P688
[7]   Corynoxine, a Natural Autophagy Enhancer, Promotes the Clearance of Alpha-Synuclein via Akt/mTOR Pathway [J].
Chen, Lei-Lei ;
Song, Ju-Xian ;
Lu, Jia-Hong ;
Yuan, Zhen-Wei ;
Liu, Liang-Feng ;
Durairajan, Siva Sundara Kumar ;
Li, Min .
JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2014, 9 (03) :380-387
[8]  
Chua K. K., 2012, HONG KONG J TRADI CH, V7, P66
[9]   Mucuna pruriens in Parkinson disease A double-blind, randomized, controlled, crossover study [J].
Cilia, Roberto ;
Laguna, Janeth ;
Cassani, Erica ;
Cereda, Emanuele ;
Pozzi, Nicolo G. ;
Isaias, Ioannis U. ;
Contin, Manuela ;
Barichella, Michela ;
Pezzoli, Gianni .
NEUROLOGY, 2017, 89 (05) :432-438
[10]   The role of neuronal growth factors in neurodegenerative disorders of the human brain [J].
Connor, B ;
Dragunow, M .
BRAIN RESEARCH REVIEWS, 1998, 27 (01) :1-39